Clinical Research Details

Clinical Research

GS-US-417-0301: A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Study Description

The purpose of this study is to see if filgotinib can be useful to treat your RA in combination with your current dose of Methotrexate (MTX).

This is a randomized, double-blind, placebo- and active-controlled study. Randomized means the study treatment you take will be chosen by chance--like flipping a coin. Double- blind means that you and your study doctor will not know what study drug you are taking. Placebo-controlled means that you may be taking a tablet or injection with no medicine in it; the placebo tablets look like the filgotinib tablets for this study and the placebo injections look like the adalimumab injections for this study.

Open Enrollment

Contact Name: Sarah Walters
Contact Phone: (904) 633-0071
Contact Email:


Principal Investigator
Gurjit S. Kaeley, M.D.

Sub Investigator
Karishma Ramsubeik, M.B.B.S. (M.D.)

Sub Investigator
Myint Thway, M.D.